文献速递胃肠外科

JCOG1001五年随访:可切除胃癌D2胃切除术中不推荐常规行滑囊切除术

Five-year follow-up of a randomized clinical trial comparing bursectomy and omentectomy alone for resectable gastric cancer (JCOG1001).
PubMed 文献 · Br J Surg · 2022-01-01

JCOG1001 III期随机试验比较滑囊切除术与单纯大网膜切除术治疗cT3-T4a胃癌,因中期分析提前终止,本文报告至少5年随访的最终更新结果。共1204例患者随机1:1分组,滑囊切除组Clavien-Dindo III-IV级腹腔脓肿发生率显著更高(5.5% vs 2.5%,P=0.008),5年总生存率两组无显著差异(74.9% vs 76.5%,校正HR=1.03,95%CI 0.83-1.27,单侧P=0.598),腹膜复发率亦无差异(12.1% vs 12.3%,P=1.000)。结论:D2胃切除术中不推荐将滑囊切除术作为cT3-T4a胃癌的标准术式。

要点

  • 滑囊切除组III-IV级腹腔脓肿发生率显著高于单纯大网膜切除组(5.5% vs 2.5%,P=0.008)。
  • 两组5年总生存率无显著差异(74.9% vs 76.5%,校正HR=1.03,95%CI 0.83-1.27)。
  • 滑囊切除未降低腹膜复发率(12.1% vs 12.3%,P=1.000)。

核心结论

  • D2胃切除术中,滑囊切除术不应作为cT3-T4a胃癌的标准术式推荐。
  • 与单纯大网膜切除术相比,滑囊切除术未改善总生存或腹膜复发,且增加腹腔脓肿风险。

研究设计与样本

  • JCOG1001为III期随机临床试验,于2010年6月至2015年3月入组1204例组织学证实的胃腺癌(cT3-T4a)患者,术中1:1随机分为滑囊切除组(602例)和单纯大网膜切除组(602例),均行D2胃切除术。
  • 主要终点为总生存,采用意向性治疗分析;因中期分析提前终止,本文报告至少5年随访的更新结果。

主要发现

  • 滑囊切除组Clavien-Dindo III-IV级腹腔脓肿发生率为5.5%,单纯大网膜切除组为2.5%(P=0.008)。
  • 更新后5年总生存率:滑囊切除组74.9%(95%CI 71.2-78.2),单纯大网膜切除组76.5%(95%CI 72.8-79.7);滑囊切除组死亡校正HR=1.03(95%CI 0.83-1.27,单侧P=0.598)。
  • 腹膜复发率:滑囊切除组12.1%,单纯大网膜切除组12.3%(P=1.000)。
  • 多变量分析中,年龄>65岁、肿瘤位于胃下三分之一或后壁、大体类型3/5、全胃切除及cT4a为总生存差的独立预测因素,而单纯大网膜切除不是。

临床怎么用

  • 对于cT3-T4a可切除胃癌行D2胃切除术,不应常规施行滑囊切除术,以单纯大网膜切除为宜。
  • 滑囊切除术增加III-IV级腹腔脓肿风险,选择术式时应权衡手术并发症。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bursectomy, the total resection of the bursa omentalis, is a standard procedure in gastrectomy for resectable gastric cancer. A phase III trial (JCOG1001) comparing bursectomy and omentectomy alone was terminated early at the interim analysis. The final results of the updated analysis after a minimum follow-up of 5 years are reported here. METHODS: Patients with histologically proven adenocarcinoma of the stomach (cT3-T4a) were randomized (1 : 1) during surgery to bursectomy or omentectomy-alone groups and then underwent D2 gastrectomy. The primary endpoint was overall survival, analysed on an intention-to-treat basis. RESULTS: A total of 1204 patients (602 bursectomy and 602 omentectomy alone) were enrolled between June 2010 and March 2015. The bursectomy group had a significantly higher incidence of Clavien-Dindo grade III-IV intra-abdominal abscess than the omentectomy-alone group (5.5 versus 2.5 per cent respectively; P = 0.008). The updated 5-year overall survival rates were 74.9 (95 per cent c.i. 71.2 to 78.2) per cent in the bursectomy group and 76.5 (72.8 to 79.7) per cent in the omentectomy-alone group; the adjusted HR for death in the bursectomy group was 1.03 (95 per cent c.i. 0.83 to 1.27) (1-sided P = 0.598). Bursectomy did not decrease peritoneal recurrence (12.1 versus 12.3 per cent respectively; P = 1.000). In a multivariable analysis, old age (above 65 years), tumour located in the lower third or posterior wall of the stomach, macroscopic type 3/5, total gastrectomy, and cT4a were independent predictors of poor overall survival, but omentectomy alone was not. CONCLUSION: In D2 gastrectomy, bursectomy is not recommended as a standard procedure for cT3-T4a gastric cancer. Registration number: UMIN000003688 (https://www.umin.ac.jp/ctr/).

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Kurokawa Y, Doki Y, Mizusawa J, et al. Five-year follow-up of a randomized clinical trial comparing bursectomy and omentectomy alone for resectable gastric cancer (JCOG1001). Br J Surg. 2022. PMID: 36369984. doi:10.1093/bjs/znac373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。